BHBenedikt Hild

Benedikt Hild

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Benedikt Hild has a total of 86 co-authors. Here are the top co-authors by number of shared publications:

  • Barbara Rehermann

    Immunology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, DHHS, Bethesda, Maryland, USA

    3 shared publications
  • Giorgio Trinchieri

    Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA

    2 shared publications
  • Ji Hoon Oh

    Immunology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, DHHS, Bethesda, USA

    2 shared publications
  • John A. McCulloch

    Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, USA

    2 shared publications
  • Jonathan H. Badger

    Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, DHHS

    2 shared publications
  • Stephan Patrick Rosshart

    Department of Microbiome Research, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany

    2 shared publications

Latest Publications

  • Open Access

    Natural microbiota confer life-long protection against obesity via an early-life, immune-mediated effect on brown adipocytes

    by Shahar Azar, Oksana Gavrilova, Greta Baker, Ji Hoon Oh, Keisuke Fukutomi, Jun Seishima, Jianping Ma, Moonhwa Kwak, Jonathan H. Badger, Giorgio Trinchieri, et al.

    Obesity is recognized as a major public health challenge. The World Obesity Federation predicts that by 2030 there will be 1.13 billion obese adults worldwide, with an estimated 1.6 million prematu...


  • Open Access

    Stage-dependent effects of systemic ASBT inhibition in a cholestasis-induced cholemic nephropathy mouse model

    by Ahmed Ghallab, Maiju Myllys, Daniela González, Adrian Friebel, Zaynab Hobloss, Reham Hassan, Hannah Schmidt, Qasim Siddiqui, Deng Zhipeng, Rama Hendawi, et al.

  • Open Access

    Laboratory mice engrafted with natural gut microbiota possess a wildling-like phenotype

    by Solveig Runge, Silvia von Zedtwitz, Alexander M. Maucher, Philipp Bruno, Lisa Osbelt, Bei Zhao, Anne M. Gernand, Till R. Lesker, Katja Gräwe, Manuel Rogg, et al.

    Conventional laboratory mice housed under specific pathogen-free (SPF) conditions are the standard model in biomedical research. However, in recent years, many rodent-based studies have been deemed irreproducible, raising questions about the suitability of mice as model organisms. Emerging evidence indicates that variability in SPF microbiota plays a significant role in data inconsistencies across laboratories. Although efforts have been made to standardize microbiota, existing microbial consortia lack the complexity and resilience necessary to replicate interactions in free-living mammals. We present a robust, feasible and standardizable approach for transplanting natural gut microbiota from wildlings into laboratory mice. Following engraftment, these TXwildlings adopt a structural and functional wildling-like microbiota and host physiology toward a more mature immune system, with characteristics similar to those of adult humans. We anticipate that adopting wild mouse-derived microbiota as standard for laboratory mouse models will improve the reproducibility and generalizability of basic and preclinical biomedical research.


  • Mikrobiom und metabolisches Syndrom – ein Henne-Ei-Problem?

    by Benedikt Hild

    Zusammenfassung Das Mikrobiom ist hinsichtlich seiner physiologischen und pathophysiologischen Relevanz im letzten Jahrzehnt immer mehr in den Fokus der Forschung gerückt. Erkenntnisgewinne über die Funktionsweise unseres Mikrobioms verdeutlichen dessen Einfluss auf den Metabolismus. Ebenso werden die Wechselwirkungen mit der Entstehung des metabolischen Syndroms offensichtlich, gleichzeitig entstehen aber neue Fragen: Wird das Mikrobiom dysbiotisch, bevor oder nachdem es zu einem pathologischen Stoffwechsel gekommen ist? Gibt es Möglichkeiten, das Darmmikrobiom zur Therapie des metabolischen Syndroms oder seiner Folgeerkrankungen zu nutzen? Ziel dieses Übersichtsbeitrags ist, jenseits des Modebegriffs „Mikrobiom“ über aktuelle Forschungsansätze zu berichten, die auch für den praktisch tätigen Internisten relevant sind.

  • Neonatal exposure to a wild-derived microbiome protects mice against diet-induced obesity

    by Benedikt Hild, Matthew S. Dreier, Ji Hoon Oh, John A. McCulloch, Jonathan H. Badger, Juen Guo, Claire E. Thefaine, Regina Umarova, Kevin D. Hall, Oksana Gavrilova, et al.

    Obesity and its consequences are among the greatest challenges in healthcare. The gut microbiome is recognized as a key factor in the pathogenesis of obesity. Using a mouse model, we show here that a wild-derived microbiome protects against excessive weight gain, severe fatty liver disease and metabolic syndrome during a 10-week course of high-fat diet. This phenotype is transferable only during the first weeks of life. In adult mice, neither transfer nor severe disturbance of the wild-type microbiome modifies the metabolic response to a high-fat diet. The protective phenotype is associated with increased secretion of metabolic hormones and increased energy expenditure through activation of brown adipose tissue. Thus, we identify a microbiome that protects against weight gain and its negative consequences through metabolic programming in early life. Translation of these results to humans may identify early-life therapeutics that protect against obesity.


  • Top Cited Papers

    Infection trains the host for microbiota-enhanced resistance to pathogens

    by Apollo Stacy, Vinicius Andrade-Oliveira, John A. McCulloch, Benedikt Hild, Ji Hoon Oh, P. Juliana Perez-Chaparro, Choon K. Sim, Ai Ing Lim, Verena M. Link, Michel Enamorado, et al.


  • Bile Acids in Control of the Gut-Liver-Axis

    by Benedikt Hild, Hauke S. Heinzow, Hartmut H. Schmidt, Miriam Maschmeier

    The liver and gut share an intimate relationship whose communication relies heavily on metabolites, among which bile acids play a major role. Beyond their function as emulsifiers, bile acids have been recognized for their influence on metabolism of glucose and lipids as well as for their impact on immune responses. Therefore, changes to the composition of the bile acid pool can be consequential to liver and to gut physiology. By metabolizing primary bile acids to secondary bile acids, the bacterial gut microbiome modifies how bile acids exert influence. An altered ratio of secondary to primary bile acids is found to be substantial in many studies. Thus, disease pathogenesis and progression could be changed by gut microbiome modification which influences the bile acid pool.